US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

AgomAb Therapeutics / Equity Capital Markets

<ul>
<li>Agomab Therapeutics (AGMB US) set IPO terms for a February 6 debut amid a busy issuance week, targeting a $731–$829 million market capitalization.</li>
<li>The company is offering 12.5 million primary ADSs at $15–$17, with proceeds funding fibrosis-focused clinical programs and pipeline expansion.</li>
<li>Backed by blue-chip biotech and crossover investors, Agomab enters public markets well capitalized ahead of key clinical milestones.</li>
</ul>


Agomab Therapeutics (AGMB US) set IPO terms for a February 6 debut amid a busy issuance week, targeting a $731–$829 million market capitalization.
The company is offering 12.5 million primary ADSs at $15–$17, with proceeds funding fibrosis-focused clinical programs and pipeline expansion.
Backed by blue-chip biotech and crossover investors, Agomab enters public markets well capitalized ahead of key clinical milestones.


AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

<ul>
<li>AgomAb Therapeutics (AGMB US) filed for a January 16 IPO, targeting a potential February debut to fund mid-stage clinical development in fibrotic diseases.</li>
<li>Lead asset ontunisertib targets fibrostenosing Crohn’s disease via GI-restricted TGFβ/ALK5 inhibition, addressing a large, underserved patient population with no approved therapies.</li>
<li>Backed by ~$330M from blue-chip investors including Fidelity, Redmile, Pfizer, and Sanofi, the company looks to enter public markets with strong validation and balance sheet strength.</li>
</ul>


AgomAb Therapeutics (AGMB US) filed for a January 16 IPO, targeting a potential February debut to fund mid-stage clinical development in fibrotic diseases.
Lead asset ontunisertib targets fibrostenosing Crohn’s disease via GI-restricted TGFβ/ALK5 inhibition, addressing a large, underserved patient population with no approved therapies.
Backed by ~$330M from blue-chip investors including Fidelity, Redmile, Pfizer, and Sanofi, the company looks to enter public markets with strong validation and balance sheet strength.


AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease

Belgium

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications. The company's pipeline includes small molecule and antibody product candidates, such as Ontunisertib (AGMB-129) for Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis. AgomAb Therapeutics was founded in 2017 and is headquartered in Antwerp, Belgium.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AgomAb Therapeutics (AGMB US)

AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

Agomab Therapeutics plans IPO debut on Feb 6, aiming for $731-$829 million market cap with 12.5 million ADSs at $15-$17 to fund fibrosis programs...

IPO Boutique

AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease

AgomAb Therapeutics files for IPO to fund mid-stage development in fibrotic diseases, targeting underserved patient population with GI-restricted...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

​Agomab Therapeutics plans IPO debut on Feb 6, aiming for $731-$829 million market cap with 12.5 million ADSs at $15-$17 to fund fibrosis programs...

IPO Boutique

AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease

​AgomAb Therapeutics files for IPO to fund mid-stage development in fibrotic diseases, targeting underserved patient population with GI-restricted...

IPO Boutique

Agomab Therapeutics plans IPO debut on Feb 6, aiming for $731-$829 million market cap with 12.5 million ADSs at $15-$17 to fund fibrosis programs...

AgomAb Therapeutics files for IPO to fund mid-stage development in fibrotic diseases, targeting underserved patient population with GI-restricted...